CL2020000272A1 - Compuesto heterocíclico y su uso. - Google Patents
Compuesto heterocíclico y su uso.Info
- Publication number
- CL2020000272A1 CL2020000272A1 CL2020000272A CL2020000272A CL2020000272A1 CL 2020000272 A1 CL2020000272 A1 CL 2020000272A1 CL 2020000272 A CL2020000272 A CL 2020000272A CL 2020000272 A CL2020000272 A CL 2020000272A CL 2020000272 A1 CL2020000272 A1 CL 2020000272A1
- Authority
- CL
- Chile
- Prior art keywords
- heterocyclic compound
- memory
- narcolepsy
- symbol
- prevention
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 108050000742 Orexin Receptor Proteins 0.000 abstract 1
- 102000008834 Orexin receptor Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO HETEROCÍCLICO QUE TIENE UNA ACTIVIDAD AGONISTA DEL RECEPTOR DE OREXINA DE TIPO 2. UN COMPUESTO REPRESENTADO POR LA FÓRMULA (I), EN DONDE CADA SÍMBOLO ES COMO SE DESCRIBE EN LA MEMORIA DESCRIPTIVA, O UNA DE SUS SALES, ES DE UTILIDAD COMO UN AGENTE PARA LA PREVENCIÓN O EL TRATAMIENTO DE NARCOLEPSIA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017150685 | 2017-08-03 | ||
JP2017248495 | 2017-12-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020000272A1 true CL2020000272A1 (es) | 2020-06-19 |
Family
ID=63452697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020000272A CL2020000272A1 (es) | 2017-08-03 | 2020-01-30 | Compuesto heterocíclico y su uso. |
Country Status (19)
Country | Link |
---|---|
US (5) | US20200207734A1 (es) |
EP (1) | EP3661923B1 (es) |
JP (2) | JP6574918B1 (es) |
KR (1) | KR102582785B1 (es) |
CN (1) | CN111051295B (es) |
AU (1) | AU2018312326B2 (es) |
BR (1) | BR112020000823A2 (es) |
CA (1) | CA3071972A1 (es) |
CL (1) | CL2020000272A1 (es) |
CO (1) | CO2020001879A2 (es) |
EC (1) | ECSP20015818A (es) |
IL (2) | IL300063B2 (es) |
MY (1) | MY202221A (es) |
PH (1) | PH12020500236A1 (es) |
SG (1) | SG11202000831XA (es) |
TW (1) | TWI790264B (es) |
UA (1) | UA125597C2 (es) |
WO (1) | WO2019027058A1 (es) |
ZA (1) | ZA202001340B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019027003A1 (ja) | 2017-08-03 | 2019-02-07 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
EP3725780B1 (en) | 2017-12-12 | 2023-03-01 | University of Tsukuba | Sulfonamide derivative or pharmaceutically acceptable acid-addition salt |
WO2020004536A1 (ja) * | 2018-06-29 | 2020-01-02 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
EP3816153B1 (en) | 2018-06-29 | 2023-10-18 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
EP3895707B1 (en) | 2018-12-12 | 2023-10-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US20220017514A1 (en) | 2018-12-12 | 2022-01-20 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
MX2021008241A (es) | 2019-01-31 | 2021-08-16 | Takeda Pharmaceuticals Co | Compuesto heterociclico y su uso. |
WO2020167701A1 (en) * | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
EP4010314B1 (en) * | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
JPWO2021100730A1 (es) * | 2019-11-19 | 2021-05-27 | ||
CA3155885A1 (en) * | 2019-11-25 | 2021-06-03 | Lewis D. Pennington | Substituted macrocyclic compounds and related methods of treatment |
US11352357B2 (en) | 2019-11-27 | 2022-06-07 | Sumitomo Dainippon Pharma Co., Ltd. | Cycloalkylurea derivative |
EP4066893A4 (en) | 2019-11-27 | 2023-12-20 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
MX2022006422A (es) * | 2019-11-27 | 2022-08-25 | Sumitomo Pharma Co Ltd | Derivado de cicloalquilurea. |
WO2021166934A1 (ja) * | 2020-02-18 | 2021-08-26 | 武田薬品工業株式会社 | ピロリジン化合物の製造方法 |
BR112023002957A2 (pt) | 2020-08-18 | 2023-04-04 | Merck Sharp & Dohme Llc | Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero |
TW202227397A (zh) * | 2020-09-03 | 2022-07-16 | 英商歐瑞夏治療公司 | 雙環的-雜環衍生物及相關用途 |
JP2023540350A (ja) | 2020-09-03 | 2023-09-22 | センテッサ ファーマシューティカルズ (オレキシア) リミテッド | 中環状または大環状ベンジル置換複素環誘導体およびオレキシン-2受容体アゴニストとしてのそれらの使用 |
US20240002397A1 (en) * | 2020-11-23 | 2024-01-04 | Merck Sharp & Dohme Llc | 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists |
US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
JP2024501641A (ja) | 2020-12-21 | 2024-01-15 | アルカームス インコーポレーテッド | 置換大環状化合物及び関連する治療方法 |
BR112023020104A2 (pt) | 2021-04-02 | 2023-11-14 | Takeda Pharmaceuticals Co | Métodos para recuperação pós-operação, para facilitar a recuperação ou reduzir o tempo de recuperação da anestesia, para prevenir ou tratar distúrbios/depressão respiratória pós-operatória ou distúrbios/depressão respiratória induzida por opioides, sedação pós-operatória ou sedação induzida por opioides e para reduzir um efeito colateral de opioides |
WO2022207935A1 (en) * | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
WO2022232025A1 (en) | 2021-04-26 | 2022-11-03 | Alkermes, Inc. | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity |
CN117529470A (zh) | 2021-04-26 | 2024-02-06 | 武田药品工业株式会社 | 用于生产吡咯烷化合物的方法 |
JP2024520396A (ja) * | 2021-05-26 | 2024-05-24 | アルカーメス,インコーポレイテッド | 置換されるカルバメート大環状化合物および関連のある治療方法 |
JP2024520395A (ja) | 2021-05-26 | 2024-05-24 | アルカーメス,インコーポレイテッド | 置換される縮合二環式大環状化合物および関連のある治療方法 |
WO2023167865A1 (en) * | 2022-03-01 | 2023-09-07 | Orexia Therapeutics Limited | Bicyclic-heterocycle derivatives and related uses |
WO2023167925A1 (en) | 2022-03-01 | 2023-09-07 | Orexia Therapeutics Limited | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses |
WO2023199091A1 (en) | 2022-04-12 | 2023-10-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2023249875A1 (en) * | 2022-06-21 | 2023-12-28 | Alkermes, Inc. | Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment |
WO2024095158A1 (en) * | 2022-10-31 | 2024-05-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
WO2024095133A1 (en) | 2022-10-31 | 2024-05-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1586584A1 (en) | 1996-08-27 | 2005-10-19 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation comprising D-amino acids |
US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
WO2000047284A2 (en) | 1999-02-12 | 2000-08-17 | Smithkline Beecham P.L.C. | Novel use of orexin receptor antagonists |
US6545127B1 (en) | 1999-06-28 | 2003-04-08 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
EP1252329A4 (en) | 1999-07-30 | 2004-12-22 | Univ Leland Stanford Junior | HYPOCRETINE AND HYPOCRETINE RECEPTORS FOR THE REGULATION OF SLEEP AND SLEEP DISORDERS |
US7112566B1 (en) | 1999-09-17 | 2006-09-26 | The Regents Of The University Of California | Systemic administration of Hypocretin-1 |
US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
WO2001074162A1 (en) | 2000-04-04 | 2001-10-11 | The Regents Of The University Of California | Treatment of sleep disorders with hypocretin-1 |
JP2006513702A (ja) | 2002-09-09 | 2006-04-27 | ヌラ インコーポレーティッド | Gタンパク質共役受容体およびその使用 |
US20080260744A1 (en) | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
DK1572133T3 (da) | 2002-12-13 | 2008-07-14 | Janssen Pharmaceutica Nv | Fremgangsmåde til identificering af modulatorer af den humane orexin-2-receptor |
WO2009049215A1 (en) | 2007-10-10 | 2009-04-16 | Wake Forest University Health Sciences | Methods to reduce the effects of sleep deprivation |
EP2092825A1 (de) | 2008-02-21 | 2009-08-26 | Bayer CropScience Aktiengesellschaft | Herbizid-Kombinationen enthaltend ein Herbizid der Klasse der Diamino-s-triazine |
US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
EP2358712A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
EP2370426A1 (en) * | 2008-12-02 | 2011-10-05 | Glaxo Group Limited | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof |
WO2012137982A2 (en) * | 2011-04-05 | 2012-10-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
TW201444849A (zh) * | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
WO2014170343A1 (en) | 2013-04-15 | 2014-10-23 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders |
WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
US20160250224A1 (en) | 2013-09-24 | 2016-09-01 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
US10172916B2 (en) | 2013-11-15 | 2019-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
US20150140015A1 (en) | 2013-11-15 | 2015-05-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of pancreatic cancer |
US9815787B2 (en) | 2013-12-12 | 2017-11-14 | University Of Tsukuba | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof |
JP6552117B2 (ja) | 2014-03-28 | 2019-07-31 | 国立大学法人 筑波大学 | 敗血症の予防治療剤 |
JP6663909B2 (ja) | 2014-08-13 | 2020-03-13 | エオラス セラピューティクス, インコーポレイテッド | オレキシンレセプターモジュレーターとしてのジフルオロピロリジン |
EP3029024A1 (en) | 2014-12-02 | 2016-06-08 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
WO2016133160A1 (ja) | 2015-02-19 | 2016-08-25 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
JP6775803B2 (ja) | 2015-06-12 | 2020-10-28 | 国立大学法人 筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
WO2017044889A1 (en) | 2015-09-10 | 2017-03-16 | The Regents Of The University Of California | Lrh-1 modulators |
TWI594181B (zh) | 2015-12-29 | 2017-08-01 | 宏正自動科技股份有限公司 | 增加顯示埠相容性的方法 |
ES2907373T3 (es) | 2016-02-04 | 2022-04-25 | Takeda Pharmaceuticals Co | Compuesto de piperidina sustituida y uso de la misma |
WO2018164191A1 (ja) | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
JP7012703B2 (ja) | 2017-03-08 | 2022-02-14 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
WO2019027003A1 (ja) | 2017-08-03 | 2019-02-07 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
WO2019112007A1 (ja) | 2017-12-07 | 2019-06-13 | 国立大学法人 筑波大学 | 鎮痛薬による眠気の予防または治療薬 |
-
2018
- 2018-08-02 JP JP2019502822A patent/JP6574918B1/ja active Active
- 2018-08-02 CN CN201880050612.8A patent/CN111051295B/zh active Active
- 2018-08-02 AU AU2018312326A patent/AU2018312326B2/en active Active
- 2018-08-02 IL IL300063A patent/IL300063B2/en unknown
- 2018-08-02 BR BR112020000823-0A patent/BR112020000823A2/pt unknown
- 2018-08-02 TW TW107126889A patent/TWI790264B/zh active
- 2018-08-02 MY MYPI2020000545A patent/MY202221A/en unknown
- 2018-08-02 EP EP18762939.9A patent/EP3661923B1/en active Active
- 2018-08-02 CA CA3071972A patent/CA3071972A1/en active Pending
- 2018-08-02 WO PCT/JP2018/029696 patent/WO2019027058A1/en unknown
- 2018-08-02 US US16/633,960 patent/US20200207734A1/en not_active Abandoned
- 2018-08-02 UA UAA202001519A patent/UA125597C2/uk unknown
- 2018-08-02 US US16/052,967 patent/US10428023B2/en active Active
- 2018-08-02 SG SG11202000831XA patent/SG11202000831XA/en unknown
- 2018-08-02 KR KR1020207005501A patent/KR102582785B1/ko active IP Right Grant
-
2019
- 2019-08-19 JP JP2019149969A patent/JP7152369B2/ja active Active
- 2019-09-20 US US16/577,449 patent/US10584097B2/en active Active
-
2020
- 2020-01-16 IL IL272087A patent/IL272087B2/en unknown
- 2020-01-30 CL CL2020000272A patent/CL2020000272A1/es unknown
- 2020-01-31 PH PH12020500236A patent/PH12020500236A1/en unknown
- 2020-02-20 CO CONC2020/0001879A patent/CO2020001879A2/es unknown
- 2020-03-02 ZA ZA2020/01340A patent/ZA202001340B/en unknown
- 2020-03-03 EC ECSENADI202015818A patent/ECSP20015818A/es unknown
- 2020-03-06 US US16/811,426 patent/US11440883B2/en active Active
-
2022
- 2022-06-22 US US17/846,830 patent/US20230063805A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020000272A1 (es) | Compuesto heterocíclico y su uso. | |
CO2018008705A2 (es) | Compuestos de piperidina sustituido y su uso | |
CL2021001973A1 (es) | Compuesto heterocíclico y su uso. | |
CL2018001181A1 (es) | Inhibidores de ret | |
CL2018001790A1 (es) | Procesos para preparar un inhibidor de jak1 y nuevas formas de este (divisional solicitud 201602748) | |
AR111346A1 (es) | Compuesto peptídico con acción activante sobre receptores gip | |
CL2022000448A1 (es) | Autoinyector (divisional solicitud no. 201903061) | |
UY35821A (es) | Compuesto heterocíclico | |
CR20160418A (es) | Nuevos compuestos biciclicos de 7 eslabones | |
BR112017007305A2 (pt) | estruturas fibrosas com aberturas e métodos para a produção das mesmas | |
ECSP18060342A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos | |
CL2016003246A1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
CR20180072A (es) | Nuevos compuestos biciclicos como inhibidores de atx | |
UY37494A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO | |
CO2020005417A2 (es) | Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd | |
CL2019002662A1 (es) | Inhibidores de ip6k. | |
BR112018014590A2 (pt) | formulações/composições compreendendo um inibidor de btk | |
CL2021001246A1 (es) | Moduladores de expresión irf5. | |
CL2016002779A1 (es) | Composición para el cuidado de la piel | |
AR106382A1 (es) | Composición adhesiva de poliuretano | |
CO2020003134A2 (es) | Moduladores de la expresión de enac | |
UY38472A (es) | Moduladores de la expresión de foxp3 | |
CL2019003234A1 (es) | Formulación de alcohol estearílico. | |
CO2019012270A2 (es) | Compuesto heterocíclico | |
CU20170134A7 (es) | 2-tiopirimidinonas |